Theranostics: The Role of Quantitative Nuclear Medicine Imaging

Chen, 2012, The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer, Thyroid, 22, 304, 10.1089/thy.2011.0203 Sgouros, 2004, Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software, J Nucl Med, 45, 1366 Strosberg, 2017, Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors, N Engl J Med, 376, 125, 10.1056/NEJMoa1607427 Graham, 2017, (68)Ga-DOTATOC imaging of neuroendocrine tumors: A systematic review and metaanalysis, J Nucl Med, 58, 1452, 10.2967/jnumed.117.191197 Vinjamuri, 2013, Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: Assessment of response, survival and toxicity, Br J Cancer, 108, 1440, 10.1038/bjc.2013.103 Afshar-Oromieh, 2015, The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions, J Nucl Med, 56, 1697, 10.2967/jnumed.115.161299 Juergens, 2019, A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors, J Clin Oncol, 37, 10.1200/JCO.2019.37.15_suppl.TPS3152 Feuerecker, 2019, Safety and Efficacy of Ac-225-PSMA-617 in mCRPC after Failure of Lu-177-PSMA, J Med Imaging Radiat Sci, 50, S20, 10.1016/j.jmir.2019.03.066 Solnes, 2020, Theranostics: Leveraging molecular imaging and therapy to impact patient management and secure the future of nuclear medicine, J Nucl Med, 61, 311, 10.2967/jnumed.118.220665 Houshmand, 2015, An update on novel quantitative techniques in the context of evolving whole-body PET imaging, PET Clin, 10, 45, 10.1016/j.cpet.2014.09.004 Lassmann, 2018, The relevance of dosimetry in precision medicine, J Nucl Med, 59, 1494, 10.2967/jnumed.117.206649 Zaidi, 2018, Novel quantitative PET techniques for clinical decision support in oncology, Semin Nucl Med, 48, 548, 10.1053/j.semnuclmed.2018.07.003 Zaidi, 2018, Towards enhanced PET quantification in clinical oncology, Br J Radiol, 91, 10.1259/bjr.20170508 Eberlein, 2017, Individualized dosimetry for theranostics: Necessary, nice to have, or counterproductive?, J Nucl Med, 58, 97S, 10.2967/jnumed.116.186841 Napel, 2018, Quantitative imaging of cancer in the postgenomic era: Radio(geno)mics, deep learning, and habitats, Cancer, 124, 4633, 10.1002/cncr.31630 Keek, 2018, A review on radiomics and the future of theranostics for patient selection in precision medicine, Br J Radiol, 91, 10.1259/bjr.20170926 O'Connor, 2008, Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives, Lancet Oncol, 9, 766, 10.1016/S1470-2045(08)70196-7 Mankoff, 2015, How imaging can impact clinical trial design: Molecular imaging as a biomarker for targeted cancer therapy, Cancer J, 21, 218, 10.1097/PPO.0000000000000116 Yankeelov, 2016, Quantitative imaging in cancer clinical trials, Clin Cancer Res, 22, 284, 10.1158/1078-0432.CCR-14-3336 Wahl, 2009, From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors, J Nucl Med, 50, 122S, 10.2967/jnumed.108.057307 O, 2016, Practical PERCIST: A simplified guide to PET response criteria in solid tumors 1.0, Radiology, 280, 576, 10.1148/radiol.2016142043 Kinahan, 2010, Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy, Semin Ultrasound CT MR, 31, 496, 10.1053/j.sult.2010.10.001 Boellaard, 2004, Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study, J Nucl Med, 45, 1519 Sullivan, 2015, Metrology standards for quantitative imaging biomarkers, Radiology, 277, 813, 10.1148/radiol.2015142202 Kessler, 2015, The emerging science of quantitative imaging biomarkers terminology and definitions for scientific studies and regulatory submissions, Stat Methods Med Res, 24, 9, 10.1177/0962280214537333 Raunig, 2015, Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment, Stat Methods Med Res, 24, 27, 10.1177/0962280214537344 Obuchowski, 2015, Statistical issues in the comparison of quantitative imaging biomarker algorithms using pulmonary nodule volume as an example, Stat Methods Med Res, 24, 107, 10.1177/0962280214537392 Obuchowski, 2015, Quantitative imaging biomarkers: A review of statistical methods for computer algorithm comparisons, Stat Methods Med Res, 24, 68, 10.1177/0962280214537390 Huang, 2015, Meta-analysis of the technical performance of an imaging procedure: Guidelines and statistical methodology, Stat Methods Med Res, 24, 141, 10.1177/0962280214537394 Kinahan, 2020, The QIBA Profile for FDG PET/CT as an imaging biomarker measuring response to cancer therapy, Radiology, 294, 647, 10.1148/radiol.2019191882 Graham, 2015, Summary of the UPICT Protocol for 18F-FDG PET/CT imaging in oncology clinical trials, J Nucl Med, 56, 955, 10.2967/jnumed.115.158402 Fraum, 2019, Measurement Repeatability of (18)F-FDG PET/CT Versus (18)F-FDG PET/MRI in solid tumors of the pelvis, J Nucl Med, 60, 1080, 10.2967/jnumed.118.218735 Quantitative I-123 and Tc-99m SPECT Profiles. Available at:https://www.rsna.org/research/quantitative-imaging-biomarkers-alliance/qiba-newsletters/2019/may.). Accessed March 14, 2020 Zhang, 2018, Performance evaluation of the next generation solid-state digital photon counting PET/CT system, EJNMMI Res, 8, 97, 10.1186/s13550-018-0448-7 Conti, 2019, The new opportunities for high time resolution clinical TOF PET, Clin Transl Imaging, 7, 139, 10.1007/s40336-019-00316-5 Sonni, 2018, Initial experience with a SiPM-based PET/CT scanner: Influence of acquisition time on image quality, EJNMMI Phys, 5, 9, 10.1186/s40658-018-0207-x Liu, 2019, Validation of MR-Based attenuation correction of a newly released whole-body simultaneous PET/MR system, Biomed Res Int, 2019, 10.1155/2019/8213215 Badawi, 2019, First human imaging studies with the EXPLORER Total-Body PET Scanner*, J Nucl Med, 60, 299, 10.2967/jnumed.119.226498 Pantel, 2020, PennPET explorer: Human imaging on a whole-body imager, J Nucl Med, 61, 144, 10.2967/jnumed.119.231845 Cherry, 2018, Total-body PET: Maximizing sensitivity to create new opportunities for clinical research and patient care, J Nucl Med, 59, 3, 10.2967/jnumed.116.184028 Zhang, 2020, Total-body dynamic reconstruction and parametric imaging on the uEXPLORER, J Nucl Med, 61, 285, 10.2967/jnumed.119.230565 Deri, 2013, PET imaging with Zr-89: From radiochemistry to the clinic, Nucl Med Biol, 40, 3, 10.1016/j.nucmedbio.2012.08.004 Pandit-Taskar, 2014, Zr-89-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer, Eur J Nucl Med Mol Imaging, 41, 2093, 10.1007/s00259-014-2830-7 Hays, 2002, MIRD dose estimate report No. 19: Radiation absorbed dose estimates from F-18-FDG, J Nucl Med, 43, 210 Wright, 2015, Theranostic imaging of Yttrium-90, Biomed Res Int, 2015, 10.1155/2015/481279 Bailey, 2013, An evidence-based review of quantitative SPECT imaging and potential clinical applications, J Nucl Med, 54, 83, 10.2967/jnumed.112.111476 Dewaraja, 2012, MIRD pamphlet No. 23: Quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy, J Nucl Med, 53, 1310, 10.2967/jnumed.111.100123 Armstrong, 2016, Activity concentration measurements using a conjugate gradient (Siemens xSPECT) reconstruction algorithm in SPECT/CT, Nucl Med Commun, 37, 1212, 10.1097/MNM.0000000000000586 Vija, 2019, ROC study and SUV threshold using quantitative multi-modal SPECT for bone imaging, Eur J Hybrid Imaging, 3, 10.1186/s41824-019-0057-3 Hutton, 2018, Advances in clinical molecular imaging instrumentation, Clin Transl Imaging, 6, 31, 10.1007/s40336-018-0264-0 Hutton, 2018, Development of clinical simultaneous SPECT/MRI, Br J Radiol, 91, 10.1259/bjr.20160690 Rault, 2007, Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131), Cancer Biother Radiopharm, 22, 423, 10.1089/cbr.2006.323 Lutathera Prescribing Information. Available at:https://hcp.lutathera.com/wp-content/uploads/2019/09/LUTATHERA_lutetium_Lu_177_dotatate_FDA_Prescribing_Information.pdf. Accessed March 15, 2020 Xofigo Prescribing Information. Available at:http://labeling.bayerhealthcare.com/html/products/pi/Xofigo_PI.pdf.). Accessed March 15, 2020 Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209607s000lbl.pdf. Accessed March 15, 2020 VISION Study. Available at: https://clinicaltrials.gov/ct2/show/NCT03511664.). Accessed March 15, 2020 Witzig, 2002, Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, J Clin Oncol, 20, 2453, 10.1200/JCO.2002.11.076 Shadman, 2018, Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus (131)I-tositumomab: Long-term follow-up of phase III randomized study SWOG-S0016, J Clin Oncol, 36, 697, 10.1200/JCO.2017.74.5083 Violet, 2019, Dosimetry of Lu-177-PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes, J Nucl Med, 60, 517, 10.2967/jnumed.118.219352 Ilan, 2015, Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using Lu-177-DOTATATE, J Nucl Med, 56, 177, 10.2967/jnumed.114.148437 Zaknun, 2013, The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 40, 800, 10.1007/s00259-012-2330-6 Barone, 2005, Patient-specific dosimetry in predicting renal toxicity with Y-90-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship, J Nucl Med, 46, 99S O'Donoghue, 2002, Hematologic toxicity in radioimmuniotherapy: Dose-response relationships for I-131 labeled antibody therapy, Cancer Biother Radiopharm, 17, 435, 10.1089/108497802760363222 Walrand, 2011, Experimental facts supporting a red marrow uptake due to radiometal transchelation in Y-90-DOTATOC therapy and relationship to the decrease of platelet counts, Eur J Nucl Med Mol Imaging, 38, 1270, 10.1007/s00259-011-1744-x Yang, 2014, Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: A meta-analysis, Acta Radiol, 55, 389, 10.1177/0284185113496679 Sadowski, 2016, Prospective Study of Ga-68-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites, J Clin Oncol, 34, 588, 10.1200/JCO.2015.64.0987 Hope, 2017, Ga-68-PSMA-11 PET imaging of response to androgen receptor inhibition: First human experience, J Nucl Med, 58, 81, 10.2967/jnumed.116.181800 Afshar-Oromieh, 2017, Diagnostic performance of Ga-68-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients, Eur J Nucl Med Mol Imaging, 44, 1258, 10.1007/s00259-017-3711-7 Pfeifer, 2012, Clinical PET of neuroendocrine tumors using Cu-64-DOTATATE: First-in-Humans study, J Nucl Med, 53, 1207, 10.2967/jnumed.111.101469 Hicks, 2019, Cu-64-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy, J Nucl Med, 60, 777, 10.2967/jnumed.118.217745 Lubberink, 2011, Quantitative imaging of I-124 and Y-86 with PET, Eur J Nucl Med Mol Imaging, 38, 10, 10.1007/s00259-011-1768-2 Rosch, 2017, The beginning and development of the theranostic approach in nuclear medicine, as exemplified by the radionuclide pair Y-86 and Y-90, Pharmaceuticals, 10, 10.3390/ph10020056 Lhommel, 2010, Feasibility of Y-90 TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres, Eur J Nucl Med Mol Imaging, 37, 1654, 10.1007/s00259-010-1470-9 Willowson, 2015, A multicentre comparison of quantitative Y-90 PET/CT for dosimetric purposes after radioembolization with resin microspheres, Eur J Nucl Med Mol Imaging, 42, 1202, 10.1007/s00259-015-3059-9 Gaykema, 2013, Zr-89- bevacizumab PET imaging in primary breast cancer, J Nucl Med, 54, 1014, 10.2967/jnumed.112.117218 Carrasquillo, 2011, I-124-huA33 antibody PET of colorectal cancer, J Nucl Med, 52, 1173, 10.2967/jnumed.110.086165 Zechmann, 2014, Radiation dosimetry and first therapy results with a I-124/I-131-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy, Eur J Nucl Med Mol Imaging, 41, 1280, 10.1007/s00259-014-2713-y Robu, 2017, Preclinical evaluation and first patient application of Tc-99m-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer, J Nucl Med, 58, 235, 10.2967/jnumed.116.178939 Sepulveda-Mendez, 2012, Specificity and sensitivity of Tc-99m-EDDA/HYNIC-Tyr(3)-octreotide (Tc-99m-TOC) for imaging neuroendocrine tumors, Nucl Med Commun, 33, 69, 10.1097/MNM.0b013e32834cecfe Bombardieri, 2010, I-131/I-123-Metaiodobenzylguanidine (mIBG) scintigraphy: Procedure guidelines for tumour imaging, Eur J Nucl Med Mol Imaging, 37, 2436, 10.1007/s00259-010-1545-7 Barrett, 2013, First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer, J Nucl Med, 54, 380, 10.2967/jnumed.112.111203 Elschot, 2013, Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo Yttrium-90 microsphere distribution after liver radioembolization, PLoS One, 8, 10.1371/journal.pone.0055742 Minarik, 2010, Y-90 bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy, J Nucl Med, 51, 1974, 10.2967/jnumed.110.079897 Cremonesi, 1999, Biokinetics and dosimetry in patients administered with In-111-DOTA-Tyr(3)-octreotide: Implications for internal radiotherapy with Y-90-DOTATOC, Eur J Nucl Med, 26, 877, 10.1007/s002590050462 Pandit-Taskar, 2008, Antibody mass escalation study in patients with castration-resistant prostate cancer using In-111-J591: Lesion detectability and dosimetric projections for Y-90 Radioimmunotherapy, J Nucl Med, 49, 1066, 10.2967/jnumed.107.049502 Ljungberg, 2016, MIRD Pamphlet No. 26: Joint EANM/MIRD guidelines for quantitative Lu-177 SPECT applied for dosimetry of radiopharmaceutical therapy, J Nucl Med, 57, 151, 10.2967/jnumed.115.159012 Marin, 2017, Accuracy and precision assessment for activity quantification in individualized dosimetry of Lu-177-DOTATATE therapy, EJNMMI Physics, 4, 10.1186/s40658-017-0174-7 Beauregard, 2011, Quantitative Lu-177 SPECT (QSPECT) imaging using a commercially available SPECT/CT system, Cancer Imaging, 11, 56, 10.1102/1470-7330.2011.0012 Spanu, 2009, I-131 SPECT/CT in the Follow-up of differentiated thyroid carcinoma: Incremental value versus planar imaging, J Nucl Med, 50, 184, 10.2967/jnumed.108.056572 Dewaraja, 2013, MIRD pamphlet No. 24: Guidelines for quantitative I-131 SPECT in dosimetry applications, J Nucl Med, 54, 2182, 10.2967/jnumed.113.122390 Robertson, 2017, Multi-isotope SPECT imaging of the Ac-225 decay chain: Feasibility studies, Phys Med Biol, 62, 4406, 10.1088/1361-6560/aa6a99 Zhang, 2019, Alpha-SPECT: Hyperspectral single photon imaging of targeted alpha-emission therapy, J Nucl Med, 60 Larsson, 2017, Quantitative gamma camera imaging of Th-227 and Ra-223 with application in Th-227 targeted alpha therapy, Eur J Nucl Med Mol Imaging, 44, S178 Ghaly, 2019, Quantitative dual isotope SPECT imaging of the alpha-emitters Th-227 and Ra-223, J Nucl Med, 60